Cargando…
1154. Safety, Tolerability, and Viral Pharmacodynamics of the IgG Monoclonal Antibody Sotrovimab Administered via Intramuscular Injection for the Treatment of Early Mild-to-Moderate COVID-19
BACKGROUND: There is a continued need for therapeutics for the treatment of COVID-19, including intramuscular (IM) agents, which will enable broader use across a variety of healthcare delivery settings. METHODS: COMET-PEAK (NCT04779879) is a 3-part study evaluating the safety, tolerability, pharmaco...
Autores principales: | Gupta, Anil K, Perez-Rodríguez, Maria Teresa, Gonzalez-Rojas, Yaneicy, Ramgopal, Moti, Free, Almena, Han, Jennifer, Moore, Jennifer, Banerjee, Rudrani, Yates, Phillip, Walker, Jill, Schnell, Gretja, Connolly, Mary Beth, Cathcart, Andrea L, Imber, Varsha, Anselm, Rabia, Winograd, Lindsay, Haeusser, Nancy, Segal, Scott, Skingsley, Andrew, Aldinger, Melissa, Peppercorn, Amanda, Moya, Jaynier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752959/ http://dx.doi.org/10.1093/ofid/ofac492.992 |
Ejemplares similares
-
1150. Resistance Analysis in the COMET-TAIL Study: Participants with Mild-to-Moderate COVID-19 Treated with Intramuscular or Intravenous Sotrovimab
por: Agostini, Maria L, et al.
Publicado: (2022) -
502. Early COVID-19 Treatment with SARS-CoV-2 Neutralizing Antibody Sotrovimab
por: Gupta, Anil K, et al.
Publicado: (2021) -
Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial
por: Shapiro, Adrienne E, et al.
Publicado: (2023) -
Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial
por: Moya, Jaynier, et al.
Publicado: (2023) -
Population pharmacokinetics and exposure‐response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID‐19
por: Sager, Jennifer E., et al.
Publicado: (2023)